Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting

被引:62
作者
Wiekhorst, F.
Seliger, C.
Jurgons, R.
Steinhoff, U.
Eberbeck, D.
Trahms, L.
Alexiou, C. [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Otorhinolaryngol Head & Neck Surg, D-8520 Erlangen, Germany
[2] Phys Tech Bundesanstalt, Berlin, Germany
关键词
magnetic drug targeting; magnetic nanoparticle;
D O I
10.1166/jnn.2006.477
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Magnetic nanoparticles can be used in medicine in vivo as contrast agents and as a drug carrier system for chemotherapeutics. Thus local cancer therapy is performed with Magnetic Drug Targeting (MDT) and allows a specific delivery of therapeutic agents to desired targets, i.e., tumors, by using a chemotherapeutic substance bound to magnetic nanoparticles and focused with an external magnetic field to the tumor after intraarterial application. Important for this therapeutic principle is the distribution of the particles in the whole organism and especially in the tumor. Therefore we used magnetorelaxometry to quantify ferrofluids delivered after MDT. Tissue samples of some mm(3) volume of a VX2 squamous cell carcinoma were measured by magnetic relaxation and the amount of iron was determined using the original ferrofluid suspension as a reference. From this the distribution of the magnetic particles within the slice of tumor was reconstructed. Histological cross-sections of the respective tumor offer the opportunity to map quantitatively the particle distribution and the vascularisation in the targeted tumor on a microscopic scale. Our data show that the integral method magnetorelaxometry and microscopic histological methods can complete each other efficiently.
引用
收藏
页码:3222 / 3225
页数:4
相关论文
共 11 条
[1]   In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles [J].
Alexiou, C ;
Jurgons, R ;
Schmid, R ;
Hilpert, A ;
Bergemann, C ;
Parak, F ;
Iro, H .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2005, 293 (01) :389-393
[2]   Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment [J].
Alexiou, C ;
Jurgons, R ;
Schmid, RJ ;
Bergemann, C ;
Henke, J ;
Erhardt, W ;
Huenges, E ;
Parak, F .
JOURNAL OF DRUG TARGETING, 2003, 11 (03) :139-149
[3]  
Alexiou C, 2000, CANCER RES, V60, P6641
[4]   Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting [J].
Alexiou, C ;
Arnold, W ;
Hulin, P ;
Klein, RJ ;
Renz, H ;
Parak, FG ;
Bergemann, C ;
Lübbe, AS .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2001, 225 (1-2) :187-193
[5]  
ALEXIOU C, IN PRESS ANTICANCER
[6]  
ALEXIOU C, 2005, IN PRESS IEEE T APPL
[7]  
Matz H, 1998, APPL SUPERCOND, V6, P577, DOI 10.1016/S0964-1807(99)00014-9
[8]   Magnetic nanoparticle relaxation measurement as a novel tool for in vivo diagnostics [J].
Romanus, E ;
Hückel, M ;
Gross, C ;
Prass, S ;
Weitschies, W ;
Bräuer, R ;
Weber, P .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2002, 252 (1-3) :387-389
[9]   SURFACE MODIFICATION OF NANOPARTICLES TO OPPOSE UPTAKE BY THE MONONUCLEAR PHAGOCYTE SYSTEM [J].
STORM, G ;
BELLIOT, SO ;
DAEMEN, T ;
LASIC, DD .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 17 (01) :31-48
[10]  
WIEKHORST F, 2005, BIOMED TECH, V50, P609